Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 6/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KYNU | Q16719 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4362880 | 0.91 | SYK (0.49) | SYKLMNASMN1; SMN2CA1CA2 | |
| SCHEMBL2518451 | 0.85 | LMNA (0.54) | SYKLMNASMN1; SMN2HTTTRPM8 | |
| SCHEMBL2518455 | 0.85 | LMNA (0.54) | SYKLMNASMN1; SMN2HTTTRPM8 | |
| SCHEMBL22775253 | 0.83 | SYK (0.55) | SYKLMNASMN1; SMN2CA1CA2 | |
| SCHEMBL10402059 | 0.81 | SYK (0.47) | SYKLMNASMN1; SMN2CA1CA2 | |
| SCHEMBL10402060 | 0.81 | SYK (0.47) | SYKLMNASMN1; SMN2CA1CA2 | |
| SCHEMBL19520946 | 0.80 | MMP2 (0.45) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL19520948 | 0.80 | MMP2 (0.45) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL27304800 | 0.80 | MMP2 (0.45) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL10403066 | 0.80 | SYK (0.46) | SYKLMNASMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286875-A1 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN | PFIZER, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286875-A1 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN | PFIZER, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286875-A1 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN | IDH3A, ACHE, SDHA | SYK 2689/4885LMNA 3329/4885SMN1; SMN2 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.